The premise of this proposal is that innate immunity may be the only resource left in HIV-1 infected individuals progressing to AIDS to deal with opportunistic infections such as MDR or XDR Mycobacterium tuberculosis (MTB). Given the CD4+ T cell population and function breakdown in AIDS, and associated loss of adaptive immunity responses and pathogen control, we believe that we can nevertheless resort to autophagy as an innate immunity process to combat MTB in HIV-infected macrophages. In this project we will delineate the previously unappreciated but rapidly emerging links between innate immunity (specifically IL-1? and pattern recognition receptors) and autophagy as an antimicrobial effector mechanism. Autophagy has been shown by us and others to eliminate intracellular MTB. Currently, there are two standard ways of inducing autophagy: by starvation and by the immunosuppressant rapamycin. Here, we propose to delineate additional immunological methods of inducing autophagy, following up on our published work showing that innate immunity pattern recognition receptors (PRR), e.g. Toll-like receptors (TLR), control autophagy. Moreover, our preliminary studies show that IL-1? can induce autophagy. In this project, we will delineate pathways for innate immunity induction of antimicrobial autophagy to understand how these newly recognized processes work. These studies will provide a foundation for use of autophagy agonists in difficult cases such as drug resistant MTB in AIDS patients. Hypothesis: We hypothesize that innate immunity receptors and mediators, specifically pattern recognition receptors (PRR) and IL1-? receptor and their downstream signaling pathways induce autophagy as an antimycobacterial mechanism. We furthermore hypothesize that agonists of innate immunity receptors will, through autophagy, eliminate M. tuberculosis in HIV-coinfected macrophages, even in the absence of CD4+ T cells.
The specific aims are: 1. Determine how IL-1? induces autophagy as an antimycobacterial innate immunity effector. 2. Delineate how TLRs induce autophagy as an antimycobacterial defense. 3. Define factors of MTB elimination by PRR-induced autophagy in HIV infected macrophages.

Public Health Relevance

We have very few resources left in AIDS to deal with dangerous infections such as MDR or XDR Mycobacterium tuberculosis. The leukocytes that normally wall off M. tuberculosis in immunologically competent people are absent or are dysfunctional in AIDS. However, there are parts of immunity called innate immunity that are relatively intact in HIV infected people, but have been thus far untapped in combating tuberculosis in AIDS. We have pioneered studies of a new innate immunity process called autophagy, whereby cells can digest portions of their cytoplasm and similarly digest unwanted microbes (such as M. tuberculosis) lodged in their interiors. The present project is aimed at connecting cell surface receptors on macrophages (the cell type in which M. tuberculosis hides) and autophagy. We wish, by stimulating such surface receptors, to enable the macrophage to digest the unwanted M. tuberculosis that it unwittingly harbors and cannot get rid of in the absence of helper lymphocytes, as happens in HIV infected individuals when they progress to AIDS. Our project will lead to novel treatments of difficult cases such as drug resistant MTB in AIDS patients.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI042999-16
Application #
8471040
Study Section
AIDS-associated Opportunistic Infections and Cancer Study Section (AOIC)
Program Officer
Lacourciere, Karen A
Project Start
1998-04-01
Project End
2014-05-31
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
16
Fiscal Year
2013
Total Cost
$383,575
Indirect Cost
$129,552
Name
University of New Mexico Health Sciences Center
Department
Genetics
Type
Schools of Medicine
DUNS #
829868723
City
Albuquerque
State
NM
Country
United States
Zip Code
87131
Mandell, Michael A; Jain, Ashish; Kumar, Suresh et al. (2016) TRIM17 contributes to autophagy of midbodies while actively sparing other targets from degradation. J Cell Sci 129:3562-3573
Chauhan, Santosh; Kumar, Suresh; Jain, Ashish et al. (2016) TRIMs and Galectins Globally Cooperate and TRIM16 and Galectin-3 Co-direct Autophagy in Endomembrane Damage Homeostasis. Dev Cell 39:13-27
Kimura, Tomonori; Mandell, Michael; Deretic, Vojo (2016) Precision autophagy directed by receptor regulators - emerging examples within the TRIM family. J Cell Sci 129:881-91
Deretic, Vojo (2016) Autophagy in leukocytes and other cells: mechanisms, subsystem organization, selectivity, and links to innate immunity. J Leukoc Biol 100:969-978
Chauhan, Santosh; Ahmed, Zahra; Bradfute, Steven B et al. (2015) Pharmaceutical screen identifies novel target processes for activation of autophagy with a broad translational potential. Nat Commun 6:8620
Deretic, Vojo; Kimura, Tomonori; Timmins, Graham et al. (2015) Immunologic manifestations of autophagy. J Clin Invest 125:75-84
Ponpuak, Marisa; Mandell, Michael A; Kimura, Tomonori et al. (2015) Secretory autophagy. Curr Opin Cell Biol 35:106-16
Chauhan, Santosh; Mandell, Michael A; Deretic, Vojo (2015) IRGM governs the core autophagy machinery to conduct antimicrobial defense. Mol Cell 58:507-21
Kimura, Tomonori; Jain, Ashish; Choi, Seong Won et al. (2015) TRIM-mediated precision autophagy targets cytoplasmic regulators of innate immunity. J Cell Biol 210:973-89
Rubinsztein, David C; Bento, Carla F; Deretic, Vojo (2015) Therapeutic targeting of autophagy in neurodegenerative and infectious diseases. J Exp Med 212:979-90

Showing the most recent 10 out of 79 publications